ATE520783T1 - Lentivirale vektoren - Google Patents

Lentivirale vektoren

Info

Publication number
ATE520783T1
ATE520783T1 AT97909437T AT97909437T ATE520783T1 AT E520783 T1 ATE520783 T1 AT E520783T1 AT 97909437 T AT97909437 T AT 97909437T AT 97909437 T AT97909437 T AT 97909437T AT E520783 T1 ATE520783 T1 AT E520783T1
Authority
AT
Austria
Prior art keywords
lentiviral vectors
vector particles
provirus
letiviruses
ltr
Prior art date
Application number
AT97909437T
Other languages
English (en)
Inventor
Alan John Kingsman
Susan Mary Kingsman
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE520783T1 publication Critical patent/ATE520783T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mushroom Cultivation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
AT97909437T 1996-10-17 1997-10-17 Lentivirale vektoren ATE520783T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9621680.9A GB9621680D0 (en) 1996-10-17 1996-10-17 Lentiviral vectors
PCT/GB1997/002858 WO1998017816A1 (en) 1996-10-17 1997-10-17 Lentiviral vectors

Publications (1)

Publication Number Publication Date
ATE520783T1 true ATE520783T1 (de) 2011-09-15

Family

ID=10801598

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97909437T ATE520783T1 (de) 1996-10-17 1997-10-17 Lentivirale vektoren

Country Status (18)

Country Link
US (1) US6235522B1 (de)
EP (1) EP0939827B1 (de)
JP (1) JP2001502903A (de)
KR (1) KR20000049250A (de)
CN (1) CN1195864C (de)
AT (1) ATE520783T1 (de)
AU (1) AU737801B2 (de)
BG (1) BG103334A (de)
CA (1) CA2268271A1 (de)
CZ (1) CZ137299A3 (de)
GB (2) GB9621680D0 (de)
HK (1) HK1018481A1 (de)
HU (1) HUP0000442A3 (de)
IL (1) IL128564A0 (de)
NO (1) NO991742L (de)
NZ (1) NZ334522A (de)
PL (1) PL332876A1 (de)
WO (1) WO1998017816A1 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924123B2 (en) * 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
WO1998051810A1 (en) 1997-05-13 1998-11-19 University Of North Carolina At Chapel Hill Lentivirus-based gene transfer vectors
FI112580B (fi) 1997-06-27 2003-12-15 Nokia Corp Kutsunsiirron reititys peruspalvelukohtaisesti
ES2245042T3 (es) 1997-09-24 2005-12-16 The Regents Of The University Of California Vectores de lentivirus de no primates y sistemas de empaquetamiento.
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
EP1088086A4 (de) 1998-06-24 2003-01-08 Musc Found For Res Dev Gewebe-spezifische sowie ziel-rna-spezifische ribozyme
US6958226B1 (en) 1998-09-11 2005-10-25 The Children's Medical Center Corp. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
EP1849873B1 (de) * 1999-04-29 2011-10-12 Gbp Ip, Llc Verfahren und Mittel zur Herstellung von sicheren, rekombinanten Lentivirusvektoren mit hohem Titer
EP1083230A1 (de) * 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Virale Replikons und von induzierenden Wirkstoffen abhängige Viren
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
EP1702983A3 (de) 2000-04-13 2007-01-10 Medical University of South Carolina Gewebespezifische und pathogenspezifische giftige Verbindungen, Ribozyme, DNAzyme und Antisenseolinukleotide sowie Anwendungen dafür
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
AU2001263160A1 (en) 2000-05-19 2001-12-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilization of non-viral sequences for minus-strand dna transfer and gene reconstitution
WO2002034929A2 (en) * 2000-10-20 2002-05-02 Whitehead Institute For Biomedical Research Expression vectors and uses thereof
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
WO2002086064A2 (en) * 2001-04-20 2002-10-31 The Salk Institute For Biological Studies Inducible expression of transfected genes
WO2002087341A1 (en) * 2001-05-01 2002-11-07 Genetix Pharmaceuticals, Inc. Novel self-inactivating (sin) lentiviral vectors
ATE527347T1 (de) * 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
NZ532060A (en) * 2001-10-02 2005-11-25 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications
EP2348119B1 (de) 2002-02-01 2017-04-26 Oxford BioMedica (UK) Limited Multicistronische lentiviraler Vektor
US7786278B2 (en) 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
DE60326444D1 (de) * 2002-04-26 2009-04-16 Inst Clayton De La Rech Verbesserte chimäre glykoproteine und pseudotypisierte lentivirale vektoren
EP1563069B1 (de) * 2002-11-22 2012-06-06 Institut Clayton De La Recherche Zusammensetzungen und systeme zur genregulierung
WO2005030927A2 (en) * 2003-09-23 2005-04-07 Uab Research Foundation Methods and compositions for in vivo inflammation monitoring
CN101124327A (zh) * 2003-10-08 2008-02-13 圣诺菲·帕斯图尔公司 经修饰的cea/b7载体
WO2005118809A2 (en) * 2004-04-29 2005-12-15 The University Of North Carolina At Chapel Hill Methods and compositions for enhancing cell adhesion properties
US20060292159A1 (en) * 2005-06-08 2006-12-28 Ranscht Barbara E Methods for the inhibition of neovascularization and cancer metastasis
GB201202516D0 (en) 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
KR101554678B1 (ko) 2012-10-19 2015-09-21 영남대학교 산학협력단 식물 바이러스를 이용한 식물체 형질전환을 위한 유전자 전달 시스템 및 이의 용도
DK3889173T3 (da) 2013-02-15 2023-10-09 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
WO2014142235A1 (ja) * 2013-03-13 2014-09-18 Li Zhong 微小胞及びその製造方法
EP3160478A4 (de) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimiertes faktor-ix-gen
EP3031923A1 (de) * 2014-12-11 2016-06-15 Institut Pasteur Lentivirale, vektorbasierte immunogene Zusammensetzung gegen Japanische Enzephalitis
SG10201913278PA (en) 2016-02-01 2020-02-27 Bioverativ Therapeutics Inc Optimized factor viii genes
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
AR110677A1 (es) 2016-10-12 2019-04-24 Bioverativ Usa Inc Anticuerpos anti-c1s y métodos para usarlos
KR102539159B1 (ko) 2016-11-07 2023-06-02 주식회사 뉴라클사이언스 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
JP7012384B2 (ja) 2017-06-27 2022-02-14 ニューラクル サイエンス カンパニー リミテッド 癌治療のための抗ｆａｍ１９ａ５抗体の用途
EP3645039A4 (de) 2017-06-27 2021-05-05 Neuracle Science Co., Ltd Verwendung von anti-fam19a5-antikörpern zur behandlung von fibrose
CN110972463B (zh) 2017-06-27 2024-05-28 纽洛可科学有限公司 抗序列相似家族19成员a5抗体在治疗青光眼中的用途
BR112019027729A2 (pt) 2017-06-27 2020-08-18 Neuracle Science Co., Ltd anticorpos anti-fam19a5 e seus usos
WO2019009979A1 (en) 2017-07-06 2019-01-10 The Medical College Of Wisconsin, Inc. NEW IN VITRO AND IN VIVO ENRICHMENT STRATEGY TARGETING CSH-DERIVED LYMPHOCYTES TRANSDUCED BY A VECTOR FOR DISEASE THERAPY
CN111527105A (zh) 2017-10-11 2020-08-11 美国比奥维拉迪维股份有限公司 诱导补体活性的方法
MX2020008152A (es) 2018-02-01 2020-11-24 Bioverativ Therapeutics Inc Uso de vectores lentivirales que expresan el factor viii.
AU2019259798A1 (en) 2018-04-24 2020-11-12 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain
AU2019265888A1 (en) 2018-05-10 2020-11-26 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
CN113365650A (zh) 2018-11-16 2021-09-07 新免疫技术有限公司 用il-7蛋白和免疫检查点抑制剂的组合***的方法
CA3121786A1 (en) 2018-12-06 2020-06-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
JP2022549932A (ja) 2019-09-30 2022-11-29 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
WO2021146191A1 (en) 2020-01-13 2021-07-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
EP4093751A1 (de) 2020-01-22 2022-11-30 Outpace Bio, Inc. Chimäre polypeptide
WO2021151006A2 (en) 2020-01-22 2021-07-29 Outpace Bio, Inc. Chimeric polypeptides
JP2023512657A (ja) 2020-02-05 2023-03-28 ワシントン・ユニバーシティ Ｉｌ－７タンパク質とｃａｒ保有免疫細胞の組み合わせで固形腫瘍を治療する方法
IL299333A (en) 2020-06-24 2023-02-01 Bioverativ Therapeutics Inc Methods for the purification of viral vectors
EP4232566A1 (de) 2020-10-22 2023-08-30 Lyell Immunopharma, Inc. Chimäre aktivierungsrezeptoren
US20230398184A1 (en) 2020-10-26 2023-12-14 Neoimmunetech, Inc. Methods of inducing stem cell mobilization
KR20230104176A (ko) 2020-11-02 2023-07-07 네오이뮨텍, 인코퍼레이티드 코로나바이러스의 치료를 위한 인터류킨-7의 용도
AU2021376396A1 (en) 2020-11-05 2023-06-08 Neoimmunetech, Inc. Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
EP4347826A1 (de) 2021-06-02 2024-04-10 Lyell Immunopharma, Inc. Nr4a3-defiziente immunzellen und verwendungen davon
WO2023056331A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2024026490A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Polynucleotides encoding linked antigens and uses thereof
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604114A (en) * 1986-05-20 1997-02-18 Dana-Farber Cancer Institute Cis-acting repression sequences, cis-acting antirepression sequences, vectors, methods of preparation and use
JPH06510181A (ja) * 1991-05-29 1994-11-17 アメリカ合衆国 Ｒｎａプロセシングの調節機能を備えた真核細胞発現ベクター
AU2419595A (en) * 1994-05-10 1995-11-29 Hisamitsu Pharmaceutical Co., Inc. Recombinant human immunodeficiency virus vector and process for producing the same
WO1995032300A1 (en) * 1994-05-23 1995-11-30 University Of Medicine & Dentistry Of New Jersey Selective biological destruction of tumor cells
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
AU5103996A (en) * 1995-03-09 1996-10-02 Bavarian Nordic Research Institute A/S Vectors carrying therapeutic genes encoding antimicrobial peptides for gene therapy
GB9510272D0 (en) 1995-05-22 1995-07-19 Isis Innovation Retroviral vectors
WO1997048277A1 (en) 1996-06-20 1997-12-24 The Salk Institute For Biological Studies Modular assembly retroviral vectors and uses thereof

Also Published As

Publication number Publication date
CA2268271A1 (en) 1998-04-30
JP2001502903A (ja) 2001-03-06
GB9621680D0 (en) 1996-12-11
IL128564A0 (en) 2000-01-31
NO991742D0 (no) 1999-04-13
NZ334522A (en) 2001-11-30
WO1998017816A1 (en) 1998-04-30
AU737801B2 (en) 2001-08-30
GB2331522A (en) 1999-05-26
EP0939827B1 (de) 2011-08-17
EP0939827A1 (de) 1999-09-08
HUP0000442A2 (hu) 2000-06-28
HK1018481A1 (en) 1999-12-24
NO991742L (no) 1999-04-13
AU4712397A (en) 1998-05-15
GB9903117D0 (en) 1999-04-07
HUP0000442A3 (en) 2001-09-28
BG103334A (en) 2000-06-30
CN1195864C (zh) 2005-04-06
GB2331522B (en) 2001-05-23
PL332876A1 (en) 1999-10-25
CN1234075A (zh) 1999-11-03
US6235522B1 (en) 2001-05-22
KR20000049250A (ko) 2000-07-25
CZ137299A3 (cs) 1999-07-14

Similar Documents

Publication Publication Date Title
ATE520783T1 (de) Lentivirale vektoren
ES2170856T3 (es) Vectores retroviricos.
DE69703974T2 (de) Retrovirale vektoren
EP0702716A4 (de) Gentherapy bei hiv-infektion und aids mit hilfe von ribozymen
CA2311641A1 (en) Pseudo-type retroviral vectors with modifiable surface capsid proteins
DE69534948D1 (de) Retrovirale vektoren zur expression in embryonalen zellen
PT975783E (pt) "vectores retrovirais, processo para a sua producao e sua utilizacao para a transferencia de genes a celulas cd4-positivas"
NO983375D0 (no) Retroviral vektor og anvendelse derav i genterapi
DE69738944D1 (de) Retrovirale vektoren
DK631387D0 (da) Virusvektor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties